AI assistant
Swedish Orphan Biovitrum — Share Issue/Capital Change 2021
Sep 30, 2021
2974_rns_2021-09-30_6f947e5f-9422-45be-9cdc-1a64f0d315d7.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
As per 30 September 2021, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi™) amounts to 307,114,495 shares. All shares are common shares. The total number of votes is 307,114,495. The increase in the number of shares and votes results from an issue of 3,298,984 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under incentive programmes and have by virtue of the conversion clause in the articles of association been converted to common shares. As per 30 September 2021 the company holds 11,969,866 common shares.
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi's revenues amounted to SEK 15.3 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 30 September 2021 at 08:00 CEST.
For more information please contact
Thomas Kudsk Larsen, Head of Corporate Communication & Investor Relations +46 767 248 830 [email protected]
Paula Treutiger, Global Head of Communication +46 733 666 599 [email protected]